These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27466490)

  • 1. Preclinical Evaluation of Combined Targeted Approaches in Malignant Rhabdoid Tumors.
    Moreno N; Kerl K
    Anticancer Res; 2016 Aug; 36(8):3883-7. PubMed ID: 27466490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
    Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
    Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapeutic targets for the treatment of malignant rhabdoid tumors.
    Nemes K; Frühwald MC
    Expert Opin Ther Targets; 2018 Apr; 22(4):365-379. PubMed ID: 29528755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
    Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
    BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
    Algar EM; Muscat A; Dagar V; Rickert C; Chow CW; Biegel JA; Ekert PG; Saffery R; Craig J; Johnstone RW; Ashley DM
    PLoS One; 2009; 4(2):e4482. PubMed ID: 19221586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB).
    Bartelheim K; Sumerauer D; Behrends U; Kodetova D; Kucera F; Leuschner I; Neumayer P; Oyen F; Rübe C; Siebert R; Schneppenheim R; Seeringer A; Vasovcak P; Frühwald MC
    Cancer Genet; 2014 Sep; 207(9):379-83. PubMed ID: 24972932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
    Caramel J; Medjkane S; Quignon F; Delattre O
    Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.
    Li T; Wang J; Liu P; Chi J; Yan H; Lei L; Li Z; Yang B; Wang X
    Oncotarget; 2017 Jul; 8(29):47269-47283. PubMed ID: 28521298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.
    Krämer KF; Moreno N; Frühwald MC; Kerl K
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
    Sredni ST; Suzuki M; Yang JP; Topczewski J; Bailey AW; Gokirmak T; Gross JN; de Andrade A; Kondo A; Piper DR; Tomita T
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28398638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.
    Frühwald MC; Biegel JA; Bourdeaut F; Roberts CW; Chi SN
    Neuro Oncol; 2016 Jun; 18(6):764-78. PubMed ID: 26755072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhabdoid tumor growth is inhibited by flavopiridol.
    Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
    Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
    Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines.
    Lünenbürger H; Lanvers-Kaminsky C; Lechtape B; Frühwald MC
    Anticancer Drugs; 2010 Jun; 21(5):514-22. PubMed ID: 20147838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
    Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
    Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1.
    Smith ME; Cimica V; Chinni S; Jana S; Koba W; Yang Z; Fine E; Zagzag D; Montagna C; Kalpana GV
    Proc Natl Acad Sci U S A; 2011 Jan; 108(1):319-24. PubMed ID: 21173237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype.
    Haberler C; Laggner U; Slavc I; Czech T; Ambros IM; Ambros PF; Budka H; Hainfellner JA
    Am J Surg Pathol; 2006 Nov; 30(11):1462-8. PubMed ID: 17063089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy.
    Kerl K; Holsten T; Frühwald MC
    Pediatr Hematol Oncol; 2013 Oct; 30(7):587-604. PubMed ID: 23848359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMARCB1 deficiency in tumors from the peripheral nervous system: a link between schwannomas and rhabdoid tumors?
    Rizzo D; Fréneaux P; Brisse H; Louvrier C; Lequin D; Nicolas A; Ranchère D; Verkarre V; Jouvet A; Dufour C; Edan C; Stéphan JL; Orbach D; Sarnacki S; Pierron G; Parfait B; Peuchmaur M; Delattre O; Bourdeaut F
    Am J Surg Pathol; 2012 Jul; 36(7):964-72. PubMed ID: 22614000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.